You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

Investigational Drug Information for BIIB104


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug BIIB104?

BIIB104 is an investigational drug.

There have been 5 clinical trials for BIIB104. The most recent clinical trial was a Phase 1 trial, which was initiated on November 15th 2018.

The most common disease conditions in clinical trials are Schizophrenia, Cognitive Dysfunction, and [disabled in preview]. The leading clinical trial sponsors are Biogen and [disabled in preview].

There are forty-three US patents protecting this investigational drug and four hundred and eighteen international patents.

Recent Clinical Trials for BIIB104
TitleSponsorPhase
A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy ParticipantsBiogenPhase 1
A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese ParticipantsBiogenPhase 1
A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy ParticipantsBiogenPhase 1

See all BIIB104 clinical trials

Clinical Trial Summary for BIIB104

Top disease conditions for BIIB104
Top clinical trial sponsors for BIIB104

See all BIIB104 clinical trials

US Patents for BIIB104

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BIIB104 ⤷  Sign Up 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides Pfizer Inc. (New York, NY) ⤷  Sign Up
BIIB104 ⤷  Sign Up Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors Pfizer Inc. (New York, NY) ⤷  Sign Up
BIIB104 ⤷  Sign Up Imidazopyridazine compounds Pfizer Inc. (New York, NY) ⤷  Sign Up
BIIB104 ⤷  Sign Up N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiaz- in-8a(8H)-YL)-1,3-thiazol-4-YL] amides Pfizer Inc. (New York, NY) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.